2009 Annual Meeting | Clinical Issues in Multiple Sclerosis

Date Sunday 04/26/09

Time 09:00 AM - 12:45 PM Add To Calendar

Session Format This program will be presented both in-person and online

On Demand This program is not expected to be available in the meeting's On Demand product.

Event Type AM Half-Day Course

Director(s) Brian G. Weinshenker, MD, FAAN

Topic(s)

Learning Objectives Participants should have an enhanced perspective on long-term impact of disease-modifying therapies for MS and how to monitor these treatments with MRI studies, neutralizing antibody determinations (especially for interferon beta) and tests to detect development of progressive multifocal leukoencephalopathy (especially for natalizumab); and have an enhanced understanding of diagnostic and therapeutic strategies for common and unusual CNS demyelinating disease.

CME Available No CME available

Core Competencies Patient Care & Procedural Skills, Medical Knowledge

Program Level Advanced

Recommended Audience Practitioner, Fellow, Resident, Nurse

Event Timeline
09:00 AM - 09:15 AM		Debate FOR Argument: MRI Is an Effective Way to Monitor Disease Activity and Individualize Treatment Decision in Patients with MS Brian G. Weinshenker, MD, FAAN
09:15 AM - 09:30 AM		Debate AGAINST Argument: MRI Is an Effective Way to Monitor Disease Activity and Individualize Treatment Decisions in Patients with MS Jeffrey A. Cohen, MD
09:30 AM - 09:35 AM		Debate Summary: MRI Is an Effective Way to Monitor Disease Activity and Individualize Treatment Decisions in Patients with MS Dean M. Wingerchuk, MD, FAAN
09:35 AM - 09:45 AM		Questions and Answers
09:45 AM - 10:00 AM		Value of Measurement of Neutralizing Antibodies in Treatment Decisions Regarding MS Therapies Giancarlo Comi, MD
10:00 AM - 10:15 AM		Debate FOR Argument: Long-Term Efficacy of Disease-Modifying Therapies in MS Is Proven/Established Giancarlo Comi, MD
10:15 AM - 10:30 AM		Debate AGAINST Argument: Long-Term Efficacy of Disease-Modifying Therapies in MS Is Proven/Established Dean M. Wingerchuk, MD, FAAN
10:30 AM - 10:35 AM		Debate Summary: Long-Term Efficacy of Disease-Modifying Therapies in MS Is Proven/Established Brian G. Weinshenker, MD, FAAN
10:35 AM - 10:45 AM		Questions and Answers
10:45 AM - 11:00 AM		Break
11:00 AM - 11:15 AM		Progressive Multifocal Leukoencephalopathy in Patients Treated with Natalizumab: Why It Happens and What We Should Do About It Jeffrey A. Cohen, MD
11:15 AM - 12:45 PM		Interactive Case Discussions: Diagnostic Difficulties, Early Management Controversies, Treatment of Refractory Cases Brian G. Weinshenker, MD, FAAN, Dean M. Wingerchuk, MD, FAAN

Faculty Disclosures
Brian G. Weinshenker, MD, FAAN	Dr. Weinshenker has received personal compensation in the range of $500-$4,999 for serving as a Consultant for CANbridge Pharmaceuticals. Dr. Weinshenker has received personal compensation in the range of $0-$499 for serving as a Consultant for CALIBR. Dr. Weinshenker has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Horizon. Dr. Weinshenker has received personal compensation in the range of $10,000-$49,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Alexion. Dr. Weinshenker has received personal compensation in the range of $10,000-$49,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Roche Group (Chugai, Genentech, Roche). Dr. Weinshenker has received personal compensation in the range of $10,000-$49,999 for serving on a Scientific Advisory or Data Safety Monitoring board for UCB Pharmaceuticals. Dr. Weinshenker has received research support from Guthy Jackson Charitable Foundation. Dr. Weinshenker has received intellectual property interests from a discovery or technology relating to health care.
Dean M. Wingerchuk, MD, FAAN	Dr. Wingerchuk has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Imcyse. Dr. Wingerchuk has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Merck. Dr. Wingerchuk has received personal compensation in the range of $500-$4,999 for serving as a Consultant for TTY Biopharm. Dr. Wingerchuk has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Reistone Biopharm. Dr. Wingerchuk has received personal compensation in the range of $10,000-$49,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Horizon Therapeutics. Dr. Wingerchuk has received personal compensation in the range of $5,000-$9,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Genentech. Dr. Wingerchuk has received personal compensation in the range of $10,000-$49,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Roche. Dr. Wingerchuk has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Novartis. Dr. Wingerchuk has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Bristol Meyer Squibb. Dr. Wingerchuk has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for UCB Pharma. Dr. Wingerchuk has received personal compensation in the range of $5,000-$9,999 for serving on a Scientific Advisory or Data Safety Monitoring board for AstraZeneca. Dr. Wingerchuk has received personal compensation in the range of $5,000-$9,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Alexion. Dr. Wingerchuk has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Abcuro. Dr. Wingerchuk has received personal compensation in the range of $10,000-$49,999 for serving as an Editor, Associate Editor, or Editorial Advisory Board Member for Wolters Kluwers.
Giancarlo Comi, MD	Dr. Comi has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Janssen. Dr. Comi has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Bristol Myers Squibb. Dr. Comi has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Novartis. Dr. Comi has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Janssen. Dr. Comi has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Bristol Myers Squibb. Dr. Comi has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Novartis. Dr. Comi has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Aspen Healthcare. Dr. Comi has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Sanofi. Dr. Comi has received personal compensation in the range of $500-$4,999 for serving as an Editor, Associate Editor, or Editorial Advisory Board Member for Sanofi. Dr. Comi has received personal compensation in the range of $500-$4,999 for serving as an Editor, Associate Editor, or Editorial Advisory Board Member for Rewind.
Jeffrey A. Cohen, MD	Dr. Cohen has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Convelo. Dr. Cohen has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Astoria. Dr. Cohen has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Bristol Myers Squibb. Dr. Cohen has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Atara. Dr. Cohen has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Biogen. Dr. Cohen has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Viatris. Dr. Cohen has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Celltrion. Dr. Cohen has received personal compensation in the range of $500-$4,999 for serving as an Editor, Associate Editor, or Editorial Advisory Board Member for Sage.

��ɫ��

��ɫ��